2 terminated. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Terminated 2 |
Follow Multiple Myeloma: new trials by email Literature Review of Multiple Myeloma trials Research Report on Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) Ixazomib, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 4 | Terminated | Takeda | 141 | 2017-11-13 | 2026-05-04 |
| Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Bortezomib, Melphalan, Prednisone - Multiple Myeloma | Phase 4 | Terminated | Basque Health Service | 24 | 2014-01-01 | 2020-01-18 |
Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hemorrhagic Disorders (2) · Hemostatic Disorders (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Plasma Cell (2) · Paraproteinemias (2) · Vascular Diseases (2)
Bortezomib (1) · Dexamethasone (1) · Lenalidomide (1) · Melphalan (1) · Prednisone (1) · ixazomib (1)
Basque Health Service (1) · Takeda (1)
Spain (1) · United States (1)